Old drugs, new tricks: targeting the aging network
What if drugs already approved for other diseases could also slow aging?
Aging is not a single process. It is driven by a cluster of interconnected mechanisms researchers call the ‘hallmarks of aging’: chronic inflammation, DNA damage, protein imbalance, mitochondrial decline, and others. Until now, these hallmarks have mostly been studied in isolation. A new study integrates them into one shared molecular network.
Mapping the hallmarks
The researchers constructed a human interactome: a map of all known protein interactions in the human body. They then identified which proteins are involved in each hallmark. The result was striking: the hallmarks do not form isolated islands but overlapping molecular modules, connected through shared network hubs.
That structure enables a targeted search. The researchers matched the activity profiles of thousands of existing drugs against this network, looking for compounds that could influence the transcriptional changes associated with aging. Transcriptional changes refer to shifts in which genes are actively expressed in a cell.
Repurposing as a shortcut
Using existing drugs for new purposes is called drug repurposing. The advantage is that their safety profiles are already largely established, shortening the path to clinical use. The study identifies multiple candidate drugs that engage aging mechanisms via the network. Which specific drugs and how strong the effect may be remains to be confirmed in follow-up research; the findings are preliminary.
From a longevity perspective, the approach is compelling because it treats aging as a systems disease rather than a collection of separate complaints. Viewing the hallmarks as a connected network allows combination interventions to be selected more deliberately.
The study provides a map and a method, not immediate treatments. Subsequent trials will need to confirm whether the identified candidates can actually slow aging processes in practice.
Search terms: network medicine interactome aging, drug repurposing hallmarks of aging, transcriptional changes aging